Link to the University of Pittsburgh Homepage
Link to the University Library System Homepage Link to the Contact Us Form

Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur

Black, DM and Kelly, MP and Genant, HK and Palermo, L and Eastell, R and Bucci-Rechtweg, C and Cauley, J and Leung, PC and Boonen, S and Santora, A and De Papp, A and Bauer, DC (2010) Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. New England Journal of Medicine, 362 (19). 1761 - 1771. ISSN 0028-4793

[img] Plain Text (licence)
Available under License : See the attached license file.

Download (1kB)


Background: A number of recent case reports and series have identified a subgroup of atypical fractures of the femoral shaft associated with bisphosphonate use. A population-based study did not support this association. Such a relationship has not been examined in randomized trials. Methods: We performed secondary analyses using the results of three large, randomized bisphosphonate trials: the Fracture Intervention Trial (FIT), the FIT Long-Term Extension (FLEX) trial, and the Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly (HORIZON) Pivotal Fracture Trial (PFT). We reviewed fracture records and radiographs (when available) from all hip and femur fractures to identify those below the lesser trochanter and above the distal metaphyseal flare (subtrochanteric and diaphyseal femur fractures) and to assess atypical features. We calculated the relative hazards for subtrochanteric and diaphyseal fractures for each study. Results: We reviewed 284 records for hip or femur fractures among 14,195 women in these trials. A total of 12 fractures in 10 patients were classified as occurring in the subtrochanteric or diaphyseal femur, a combined rate of 2.3 per 10,000 patient-years. As compared with placebo, the relative hazard was 1.03 (95% confidence interval [CI], 0.06 to 16.46) for alendronate use in the FIT trial, 1.50 (95% CI, 0.25 to 9.00) for zoledronic acid use in the HORIZON-PFT trial, and 1.33 (95% CI, 0.12 to 14.67) for continued alendronate use in the FLEX trial. Although increases in risk were not significant, confidence intervals were wide. Conclusions: The occurrence of fracture of the subtrochanteric or diaphyseal femur was very rare, even among women who had been treated with bisphosphonates for as long as 10 years. There was no significant increase in risk associated with bisphosphonate use, but the study was underpowered for definitive conclusions. Copyright © 2010 Massachusetts Medical Society.


Social Networking:
Share |


Item Type: Article
Status: Published
CreatorsEmailPitt UsernameORCID
Black, DM
Kelly, MP
Genant, HK
Palermo, L
Eastell, R
Bucci-Rechtweg, C
Cauley, JJCauley@edc.pitt.eduJCAULEY
Leung, PC
Boonen, S
Santora, A
De Papp, A
Bauer, DC
Date: 13 May 2010
Date Type: Publication
Journal or Publication Title: New England Journal of Medicine
Volume: 362
Number: 19
Page Range: 1761 - 1771
DOI or Unique Handle: 10.1056/nejmoa1001086
Schools and Programs: Graduate School of Public Health > Epidemiology
Refereed: Yes
ISSN: 0028-4793
Date Deposited: 12 May 2015 19:57
Last Modified: 02 Feb 2019 15:55


Monthly Views for the past 3 years

Plum Analytics

Actions (login required)

View Item View Item